Intact Vascular Inc has raised $20m in the first of a two-tranche series C financing round, which saw the participation of New Enterprise Associates Inc HIG BioVentures LLC and Quaker Partners Management LP.
The second tranche is expected to be closed later in 2018.
The proceeds from the financing round are intended to be used to fund pre-market approval (PMA) of the tack endovascular system for the treatment of post-angioplasty dissections above the knee.
Based in the US, Intact Vascular is a medical device company.
The test is based on MIODx’s ClonoMap™ immune sequencing platform. It is designed to predict patient response to immunotherapy. It will be co-developed at DiaCarta’s CLIA labs in California, US, and Nanjing, China.
The strategic collaboration enables DiaCarta and MIODx to develop a diagnostic test for immunotherapy.
Tela Bio Inc has reached an agreement to raise funds through a series B financing round led by Checkmate Capital.
The company plans to use the funds to improve patient care and surgical outcomes. TELA Bio also proposes to reduce the surgery costs.
Based in the US, TELA Bio is a provider of surgical products for use in ventral hernia repair and abdominal wall reconstruction.
Alphatec Holdings Inc plans to issue 36,129,060 shares through a public offering of its common stock, priced at $0.0001 a share.
Durham Jones and Pinegar have been appointed as the company’s legal advisors for the offering.
Based in the US, Alphatec Holdings is a medical device company involved in the design, development and marketing of spinal fusion technology products.
Unicon Optical Co Ltd intends to raise TWD525.12m ($17.96m) through a rights offering of 35,008,200 shares of its common stock priced at TWD15 ($0.51) a share.
Existing shareholders will be eligible to purchase 270 shares for every 1,000 shares held.
Unical Optical has also announced the issue of 4.9 million shares to its existing employees.
The proceeds are intended to be used for working capital purposes and to expand Unicon Optical’s new plant in Taichung.
Based in Taiwan, Unical Optical is a manufacturer and distributor of contact lenses.
The funds will be used by the company to develop and clinically validate a molecular test for stratifying glioblastoma patients.
Based in the US, Isoma Diagnostics is a developer of diagnostic tools for glioblastoma.